Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel
Red mite vaccine research receives funding
Grant awarded for development of vaccine

The Biotechnology and Biological Sciences Research Council (BBSRC) has awarded funding of £550,000 to the Moredun Research Institute in Scotland, in collaboration with Pfizer Animal Health.

The research grant has been awarded to boost research into the development of a vaccine to protect hens against red mites.

Red mite attacks on hens can cause serious health problems, leading to anaemia, feather-pecking and an increased incidence of cannabilism. Dr Alisdair Nisbet, who is heading the project at Moredun speaks of the growing problems posed by red mites:

"Controlling mite populations is now a major problem, with most pesticides affording only limited or short-lived reduction in the population of mites.

"There is also the issue of development of drug resistance and environmental contamination, which means there is an urgent need to develop alternative control strategies."

The research aims to determine whether laying hens can be vaccinated using specific extracts of the mites, to induce an immune response that will kill the mites when they take a blood meal. Trials have been ongoing at Moredun since 2006, achieving approximately 75% death rate amongst red mites coming into contact with the prototype vaccine, according to Nisbet.

"[This] has been a real positive," says Nisbet "but clearly cultivating red mites for extracts is not appealing, so this new project with Pfizer and BBSRC is designed to be more commercially oriented.

"Our goal is to identify the bits of the mite that will induce the best immune responses in the hens and produce large quantities of these, using recombinant technologies to enable large-scale vaccination trials to take place."

Funding is in place for the next three years, and it is hoped that a new prototype vaccine will be available by the end of this period, which could then be made commercially.

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'